Powles, T. Et Al. 2021. 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6 .

Powles, T., Csoszi, T., ÖZGÜROĞLU, M., Matsubara, N., Geczi, L., Cheng, S. Y., ... Fradet, Y.(2021). 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

Powles, Thomas Et Al. "1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Powles, Thomas Et Al. "1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Powles, T. Et Al. (2021) . "1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

@article{article, author={Thomas Powles Et Al. }, title={1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}